您好,欢迎光临世界标品! 登录 注册(订药物标准品请用邮件联系我们)

中国医药研发对照标品提供商
Non-clinical Research-used
Medicine Sample Provider

当前本网站药物产品种数共 8420 处方药 8047 非处方药 267 保健品/医疗用具 106

世界标品医药目录搜索(中英文):
世界各国官方药品目录搜索(英文):
世界标品医药知识搜索(中英文):

联系方式
国内客服电话:
国际免费电话:


QQ客服1:1793093587
QQ客服2:1586083059
QQ客服3:2786706041
QQ客服6:2992753224
QQ客服7:2394834588

咨询邮箱:
scimed.shanghai@shijiebiaopin.com
info@shijiebiaopin.com
pharmacy.shijiebiaopin1@gmail.com
pharmacy.shijiebiaopin2@gmail.com

  药店国别: 日本药房
产地国家: 日本
所属类别: 心血管系统药物->抗心率失常药物
处方药:处方药
包装规格: 150毫克/瓶 5瓶/盒
计价单位:
   
生产厂家中文参考译名:
小野药品工业公司
生产厂家英文名:
Ono Pharmaceutical Co., Ltd.
该药品相关信息网址1:
http://www.ono.co.jp/
原产地英文商品名:
Onoact(オノアクト)150mg/vial 5vials/box
原产地英文药品名:
Landiolol
中文参考商品译名:
Onoact(オノアクト)150毫克/瓶 5瓶/盒
中文参考药品译名:
兰地洛尔
原产地国家批准上市年份:
0000/00/00
英文适应病症1:
Arrhythmia
英文适应病症2:
Atrial fibrillation
英文适应病症3:
Atrial flutter
英文适应病症4:
Sinus tachycardia
临床试验期:
完成
中文适应病症参考翻译1:
心律失常
中文适应病症参考翻译2:
心房纤维性颤动
中文适应病症参考翻译3:
心房扑动
中文适应病症参考翻译4:
窦性心动过速
药品信息:

---------------------------------------------------------------
 详细处方信息以本药内容附件PDF文件(201032321370727.pdf)的“原文Priscribing Information”为准
---------------------------------------------------------------
部分中文Onoact处方资料(仅供参考)

    抗心律失常药兰地洛尔。2002年7月,日本小野药品工业公司开发的手术时心动过速性心律失常(心房纤维性颤动、心房扑动及窦性心动过速)治疗药兰地洛尔(Onoact,landiolol)获得厚生省批准。手术时,由于气管内插管及拔管、切开皮肤以及手术操作等对身体的各种刺激,引起交感神经兴奋,释放出过剩的儿茶酚胺,使心搏数增加,易引发心动过速性心律失常。特别是伴有缺血性心脏疾病及高血压的患者,仅仅由于心搏数增加就会增强心脏的负荷,从而引起冠状动脉等缺血。兰地洛尔即是针对于此而开发的药品。

    作为一种选择性β1受体阻断药,兰地洛尔主要拮抗存在于心脏的β1受体,通过抑制由儿茶酚胺引起的心搏数增加,改善心动过速性心律失常。它在血中半衰期极短,约为4分钟。与现有的β受体阻断药不同,兰地洛尔专用于手术时心动过速性心律失常的紧急处置。

  手术时,由于气管内插管及拔管、切开皮肤以及手术操作等对身体的各种刺激,引起交感神经兴奋,释放出过剩的儿茶酚胺,使心博数增加,易引发心动过速性心律失常。特别是伴有缺血性心脏疾病及高血压的患者,仅仅由于心博数增加就会增强心脏的负荷,从而引起冠状动脉等缺血。

  Onoact即是针对于此而开发的药品。本品为选择性β1受体阻断药,主要拮抗存在于心脏的β1受体,通过抑制由儿茶酚胺引起的心博数增加,改善心动过速性心律失常。本品血中半衰期极短,约为4分钟。与现有的β受体阻断药不同,本品专用于手术时心动过速性心律失常的紧急处置。

  本品1安瓿中含有盐酸兰地洛尔50mg。通常,以每分钟0.125mg/kg的速度静脉内给药1分钟,然后调节速度在每分钟0.01~0.04mg/Kg静脉内持续给药。


Announcement of the Launch of Onoact® 50 for Injection, Japan's First Short-Acting Selective β1 Blocker
 
Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka City, President: Kimiichiro Matsumoto) will launch Onoact® 50 for injection, the drug for intraoperative tachyarrhythmia (atrial fibrillation, atrial flutter and sinus tachycardia), on September 6, 2002.

During operation, various invasive procedures on a living body, such as endotracheal intubation, extubation, skin incision and other surgical procedures, facilitate the excessive discharge of catecholamine (noradrenaline, adrenalin, etc.) mainly from the sympathetic nerve, leading to an increase in heart rate, as well as tachyarrhythmia.

Especially in patients with ischemic heart disease and/or hypertension, even a slightly increased heart rate may constitute an additional burden on the heart, and induce ischemia at coronary artery etc. Therefore, the development of a drug that can be easily titrated for emergency treatment of intraoperative tachyarrhythmia has long been awaited.

Onoact® 50 for injection, which has been developed to fulfill these medical needs, improves tachyarrhythmia by selectively blocking β1 receptors located chiefly in the heart, and by inhibiting the action of catecholamine that raises the heart rate.

Onoact® 50 for injection can be used in emergency treatment of intraoperative tachyarrhythmia, because this fast-acting drug can be easily titrated for its very short half-life in blood (approx. 4 min). We expect that Onoact® 50 for injection will be widely used as an innovative frontline drug.

Product Profile of Onoact® for Injection

Nonproprietary name : Landiolol hydrochloride

Active ingredient : 50 mg landiolol hydrochloride per vial

Indications : Emergency treatment for intraoperative tachyarrhythmia (atrial fibrillation, atrial flutter and sinus tachycardia)

Dosage and administration : Landiolol hydrochloride is intravenously administered at 0.125 mg/kg/min for one minute, and at 0.04 mg/kg/min thereafter. The dosage should be appropriately adjusted between 0.01 and 0.04 mg/kg/min, based on the heart rate and blood pressure to be measured during the infusion.

Package : 5 vials or 10 vials of Onoact® for injection

Manufactured and distributed by : Ono Pharmaceutical Co., Ltd.

---------------------------------------------------------------
 详细处方信息以本药内容附件PDF文件(201032321370727.pdf)的“原文Priscribing Information”为准
---------------------------------------------------------------

更新日期: 2018-09-09
附件:




 
调控比例: 100%
订购表单下载
Copyrights © 2010,2011,2012 www.ShiJieBiaoPin.com, Inc., All rights Reserved www.ShiJieBiaoPin.com, Inc.
客服工作时间:太平洋时间18:00-24:00
国内客服电话:     国际免费电话:
友情提示:以上电话为免费电话,无需您承担任何费用,世界标品提供中文客服,请您放心拨打!
电子邮箱:info.shijiebiaopin.com@gmail.com, info@shijiebiaopin.com